Royal Bank Of Canada cut shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from an outperform rating to an underperform rating in a report published on Friday, MarketBeat.com reports. They currently have $21.00 price objective on the stock, down from their prior price objective of $37.00.

TEVA has been the subject of several other research reports. Vetr lowered Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $32.27 price objective for the company. in a research note on Tuesday, July 4th. BidaskClub raised Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a research note on Wednesday, July 5th. Wells Fargo & Company reissued a hold rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a research note on Thursday, June 22nd. Finally, Jefferies Group LLC reissued a hold rating and set a $33.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. One equities research analyst has rated the stock with a sell rating, twenty-two have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Hold and an average price target of $39.81.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 6.84% during mid-day trading on Friday, reaching $19.19. The company had a trading volume of 32,607,904 shares. Teva Pharmaceutical Industries Limited has a 12-month low of $19.15 and a 12-month high of $55.45. The stock has a 50-day moving average of $32.05 and a 200 day moving average of $32.28. The company has a market capitalization of $19.50 billion, a price-to-earnings ratio of 246.03 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the business earned $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Royal Bank Of Canada Lowers Teva Pharmaceutical Industries Limited (TEVA) to Underperform” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/royal-bank-of-canada-lowers-teva-pharmaceutical-industries-limited-teva-to-underperform.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 0.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,680,562 shares of the company’s stock worth $89,048,000 after buying an additional 23,246 shares in the last quarter. GAM Holding AG increased its position in shares of Teva Pharmaceutical Industries Limited by 23.2% in the second quarter. GAM Holding AG now owns 41,900 shares of the company’s stock worth $1,392,000 after buying an additional 7,900 shares in the last quarter. Analyst IMS Investment Management Services Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited by 8.4% in the second quarter. Analyst IMS Investment Management Services Ltd. now owns 9,051 shares of the company’s stock worth $300,000 after buying an additional 700 shares in the last quarter. One Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 2.7% in the second quarter. One Capital Management LLC now owns 36,307 shares of the company’s stock worth $1,206,000 after buying an additional 949 shares in the last quarter. Finally, RiverPoint Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 9.1% in the second quarter. RiverPoint Capital Management LLC now owns 15,836 shares of the company’s stock worth $526,000 after buying an additional 1,325 shares in the last quarter. Institutional investors own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.